image description

Tag: voclosporin

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […] Read More

Aurinia Moves Voclosporin Closer to FDA Approval for Lupus Nephritis

March 16, 2020 The Lupus Research Alliance is pleased to share an announcement from Aurinia Pharmaceuticals that moves its potential treatment for lupus nephritis, voclosporin, one step closer to approval by the U.S. Food and Drug Administration (FDA).  The Company announced in a press release March 16 that it has started a Rolling Submission of […] Read More

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] Read More

Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid

November 8, 2019 Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact the levels of mychophenolate acid (MPA), the main ingredient  in the common standard treatment mycophenolate mofetil (CellCept®) for lupus nephritis. The drug-drug interaction (DDI) study was requested by the Food and Drug Administration to measure […] Read More

Good News from Aurinia Pharmaceuticals for Lupus Nephritis

September 25, 2018 Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of schedule.  The company reported in a press release issued today that due to high patient demand, the target number of patients was surpassed with 358 lupus nephritis (LN) patients enrolled in sites across 27 countries. […] Read More

Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced top-line results from its Phase IIb AURA-LV (AURA) study in lupus nephritis (LN). At 48 weeks, the trial met the complete and partial remission (“CR”/ “PR”) endpoints, demonstrating statistically significantly greater CR […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates